Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hegelei Pharmaceutical Constructs Plant In Dalian

This article was originally published in PharmAsia News

Executive Summary

Hegelei Dalian Pharmaceutical recently commenced construction on its RMB 803 million ($117 million) project on Dalian's Changxing island. On a site measuring 200,000 square meters, the company will finish the first phase of construction on its plant this October, complete manufacturing facilities installation and testing this December, and go into operation by end of the year. Hegelei has signed a letter of intent with German firm Maxi, a large pharmaceutical business distributing medium- and high-end anti-tumor drugs. The companies will jointly establish the largest clinical research outsourcing base in Liaoning. In addition, Hegelei will act as an agent for Maxi to bring the latter's anti-tumor drugs into China. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072102

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel